Botanix Pharmaceuticals Limited

BOT

AU000000BOT2

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-19 am EDT			5-day change	1st Jan Change
0.225 ^AUD	0.00%		+9.76%	+18.42%

Mar. 18	Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index	CI
Feb. 27	Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2021

August 26, 2021 at 07:33 pm EDT

Botanix Pharmaceuticals Limited announced earnings results for the full year ended June 30, 2021. For the full year, the company announced net loss was AUD 3.334 million compared to AUD 16.730 million a year ago. Basic loss per share from continuing operations was AUD 0.0034 compared to AUD 0.0179 a year ago.

Latest news about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication	Jan. 21	MT
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%	Dec. 20	MT
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%	Dec. 13	MT
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication	Dec. 04	MT
Botanix Pharmaceuticals Limited Receives Feedback from FDA	Dec. 03	CI
Botanix Pharmaceuticals Completes Nearly AU$14 Million Institutional Placement	Dec. 01	MT
Botanix Pharmaceuticals to Raise AU$13.5 Million in Placement; Shares Fall 3%	Nov. 26	MT
Botanix Pharmaceuticals Signs Telehealth Deal for Dermatological Product	23-10-23	MT
Botanix Pharmaceuticals Secures Conditional US FDA Clearance for Use of 'Sofra' Trade Name	23-10-16	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX Emerging Companies Index	23-09-18	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Botanix Pharmaceuticals Promotes COO to CEO	23-08-25	MT
Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer	23-08-24	CI
Botanix Pharmaceuticals Raises Nearly AU$13 Million Via Institutional Placement	23-07-21	MT
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea	23-06-05	MT
Botanix Pharmaceuticals Limited Announces Company Secretary Changes	23-04-16	CI
Botanix Pharmaceuticals Completes AU$10 Million Placement	23-04-13	MT
Botanix Pharmaceuticals to Raise AU$10 Million in Placement	23-04-05	MT
US FDA Completes Mid-Cycle Review of Botanix Pharmaceuticals’ Dermatological Drug	23-04-03	MT
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Botanix Pharmaceuticals' Dermatological Drug Enters US FDA Review	22-12-08	MT
Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review	22-12-07	CI
Botanix Pharmaceuticals to Raise $1.9 Million Under Share Purchase Plan	22-11-09	MT

Chart Botanix Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis and acne respectively. It is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
BOTANIX PHARMACEUTICALS LIMITED	+18.42%	228M
MERCK KGAA	+1.32%	67.71B
KYOWA KIRIN CO. LTD.	+10.08%	9.03B
SK BIOPHARMACEUTICALS CO., LTD.	-17.63%	4.71B
YUHAN CORPORATION	+0.73%	3.76B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+16.55%	3.66B
INDIVIOR PLC	+27.76%	2.55B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.11%	2.31B
BETTA PHARMACEUTICALS CO., LTD.	-30.09%	2.08B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.15%	1.94B